PharmaCielo ( (TSE:PCLO) ) has issued an announcement.
PharmaCielo reported a significant financial turnaround in Q4 2024, achieving a 143% year-over-year sales growth with total revenue reaching $3.54 million. The company has improved its cash flow and adjusted EBITDA, reflecting strong sales growth and reduced costs. With strategic expansion into new markets and cost optimization, PharmaCielo is well-positioned for continued revenue momentum and expects positive EBITDA and cash flow in 2025.
More about PharmaCielo
PharmaCielo Ltd. is a global cannabis products company and Colombia’s leading cultivator and producer of dried flower and medicinal-grade cannabis extracts. The company focuses on expanding its international market presence and diversifying its product portfolio beyond CBD isolate to meet the evolving needs of its global customer base.
YTD Price Performance: -12.00%
Average Trading Volume: 6,257
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.57M
For detailed information about PCLO stock, go to TipRanks’ Stock Analysis page.